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Although the risk of neurologic
complications cannot be completely
avoided after surgical revasculariza-
tion and is most likely associated
with the underlying risk profile,1 we
agree that atherosclerosis of the as-
cending aorta is among the most im-
portant predictors for the occurrence
of stroke. Epiaortic ultrasonography
has been demonstrated to be more ac-
curate than digital palpation in the de-
tection of aortic atherosclerosis2 and
can be considered the standard of
care for the detection and character-
ization of aortic plaques in the ascend-
ing aorta. Despite this knowledge,
epiaortic ultrasonography is not estab-
lished for routine use in most centers.3
The potential benefit of combining
off-pump and aortic no-touch tech-
niques has been repeatedly shown to
be a significantly reduced stroke
rate.4 Although in situ grafting may
be considered the criterion standard
whenever possible, for free graft use
requiring proximal anastomosis, our
series has clearly shown that the use
of the HEARTSTRING device (MA-
QUET Cardiovascular LLC, San
Jose, Calif) yields stroke rates compa-
rable to those achieved with no-touch,
in situ techniques.3
We acknowledge the most recent
meta-analysis, which included 8 stud-
ies with a total of 819 patients with1232 The Journal of Thoracic andapooled stroke rate of 1.9% (95% con-
fidence interval, 0.8%–4.5%) with the
use of the HEARTSTRING device5;
however, it appears that in 6 of these
studies (accounting for 88% of all in-
cluded patients; 719/819), the stroke
rate was either 0% (5 studies; n ¼
305 patients) or 0.5% (1 study; n ¼
412 patients), whereas in only 2 stud-
ies, accounting for only 100 patients
(12%; n¼ 19 and n¼ 81), were stroke
rates substantially higher at 3.7% (ac-
counting for 3 events) and 5.2% (ac-
counting for 1 event).5 In contrast, the
report of Hilker and colleagues,6 repre-
senting the largest series of the evalu-
ated studies, supports our findings
highlighting the potential benefit of
the HEARTSTRING device with re-
gard to a reduction in stroke rate.
We agree that a prospective, ran-
domized trial in combination with
the standardized application of epi-
aortic ultrasonography would be ideal
to assess the potential clinical value of
clampless devices such as the
HEARTSTRING device in reducing
neurologic complications.
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THORACOSCOPIC SURGERY
USING 3-DIMENSIONAL
TAILOR-MADE VIRTUAL LUNG
To the Editor:
I read the article titled ‘‘Simulat-
ing video-assisted thoracoscopic lo-
bectomy: a virtual reality cognitive
task simulation’’ by Solomon and
colleagues1 with amazement, and I
applaud their efforts to adopt and
improve new technology. Their ef-
forts are not only very important in
contributing to the education of
young thoracic surgeons but are
also of help to senior surgeons edu-
cating young surgeons. It is impor-
tant to practice the steps involved
in thoracoscopic surgery on one ele-
ment that was absent in the work by
Solomon and associates1—that is,
the ability to simulate anatomic
variability.
Thoracic lobectomy for lung cancer
has been gaining widespread popular-
ity, particularly in the treatment of
early-stage lung cancer, and thoraco-
scopic segmentectomy has also been
conducted in some institutes. How-
ever, anatomic variations in the pul-
monary vessels carry a potential risk
of uncontrollable intraoperative
bleeding; therefore, it is necessary to
emphasize this issue while educating
young surgeons. The education of
young thoracic surgeons is undoubt-
edly important; however, it is far
more difficult to teach thoracoscopic
surgery than it is to teach thoracotomy
surgery. During thoracotomy surgery,
senior surgeons can touch the organ
directly with forceps or fingers to indi-
cate the point of division. During thor-
acoscopic surgery, surgeons do not
touch the monitor to prevent bacterial
FIGURE 1. A, Tailor-made virtual lung showing the 3-dimensional pulmonary artery (pink), vein (blue), and bronchus (yellow). B, Area for resection is
determined on the virtual lung (apicoposterior segmentectomy [S1þ2], between black lines). Thewhite lines represent the dividing points of the vessels and
bronchus for both simulation surgery and actual complete thoracoscopic segmentectomy. C, The images are processed by radiology technicians to evaluate
individual lungs. D, Regional anatomy is confirmed on a picture archiving and communication system during a complete thoracoscopic apicoposterior seg-
mentectomy (S1þ2).
Letters to the Editorcontamination and can only roughly
indicate the point of division. There-
fore, teaching young surgeons be-
comes difficult. Furthermore, the
occurrence of massive bleeding dur-
ing thoracoscopic hilar maneuvers is
a far more serious complication than
that during thoracotomy surgery.
Therefore, simulating thoracoscopic
lobectomy will provide young sur-
geons with valuable experience before
actual surgery.
Kanzaki and colleagues2 advocate
simulation surgery for thoracic sur-
geons by creating 3-dimensional pul-
monary model images on a personal
computer. This is also an interesting
method, because students can prepare
the images themselves before sur-
gery.2 However, it is time consuming
for thoracic surgeons to create such
images before surgery.
I recommended the following pro-
cess for thoracic surgeons at our hos-
pital. Patients scheduled to undergo
thorocosopic lobectomy or segmen-
tectomy were routinely examined byThe Journalenhanced chest computed tomogra-
phy. These images were processed
(volume analyzer Synapse Vincent,
Fujifilm Medical, Tokyo, Japan) by
radiology technicians within approxi-
mately 10 minutes to evaluate the
individual lungs, including structures
such as tracheobronchial trees, pul-
monary vessels, parenchyma, and
pulmonary tumors, after subtracting
osseous tissues (Figure 1).3-5 These
images were termed ‘‘tailor-made
virtual lungs’’ and were transferred
to a picture archiving and
communication system in which the
individual lung could be viewed,
rotated, and magnified on monitors
throughout our hospital, including
those in the operating rooms, wards,
and outpatient offices. Because the
surgeon was able to refer to these
tailor-made virtual lungs at any point
of time in any place, simulation sur-
gery identifying the bronchi and ves-
sels in the affected segments could
be performed both before and during
surgery. The tailor-made virtual lungof Thoracic and Cardiovascular Surgeroffers 3-dimensional images of the
lung that cannot be obtained by
reviewing the axial and sagittal im-
ages of conventional computed to-
mography scans.
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DIAGNOSIS OF
HYPERTROPHIC
CARDIOMYOPATHY
To the Editor:
With interest, we read the recent
guideline for hypertrophic cardiomy-
opathy (HCM) and highly appreciate
the useful clinical information.1
HCM is a pathophysiologically het-
erogeneous condition. We agree with
the authors that there is comprehen-
sive evidence that mutations in 8
genes encoding proteins of, or associ-
ated with, the sarcomere can cause
HCM. These are, as stated in chapter
6 of the guideline, the genes encoding
b myosin heavy chain, myosin bind-
ing protein C, troponin T, troponin I,
a-tropomyosin, actin, regulatory light
chain, and essential light chain. How-
ever, only about 40% to 60% of HCM
cases can be attributed to these 8
genes.2,3
More recently, a ninth gene was
convincingly linked to HCM after
a genome-wide linkage analysis. Mu-
tations in CSRP3 encoding muscle
LIM protein were shown to co-
segregate with HCM in several fami-
lies in whom gene mutations in the 8
incriminated sarcomeric proteins had
been previously excluded.4 All these
mutations affected highly conserved
residues and were not found in the
control genomes. Linkage analysis
with a highly significant 5.9 logarithm
of the odds score in a single large
family provided additional genetic ev-
idence. Physicians and geneticists un-
aware of the mutation status ensured
an unbiased attribution of disease1234 The Journal of Thoracic andstatus and an unbiased genome-wide
linkage analysis in that family.5 Fur-
thermore, functional data supported
the genetic results. Cardiomyocyte
disarray was observed in CSRP3
mutation-positive cardiac tissue from
patients with HCM. The findings indi-
cate that CSRP3 mutations cause
‘‘true’’ HCM and not merely a HCM
phenocopy.
Although CSRP3 mutations in pa-
tients with HCM are not common
(<5%), we believe that there is con-
vincing, scientific evidence that the
gene should be included in the list of
confirmed HCM disease genes.
TPM1 and ACTC (encoding a-tropo-
myosin and actin) mutations occur at
a frequency not much different than
CSRP3 mutations. The prevalence of
HCM disease genes is also related to
ethnicity. Such patterns require active
surveillance of disease genes and
CSRP3 should be included. To learn
more about the ethnic spectrum of
disease genes and specific founder
mutations we propose including all
well-established disease genes into
scientific genetic screening analyses.
Muscle LIM protein is not confined
solely to sarcomeric localizations but
can be localized to the sarcolemma
and to the cell nucleus. Mechanisti-
cally, there is much to be learned
about this protein, its gene, and their
contributions to HCM. We therefore
wish to draw attention to CSRP3.
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STRATEGY FOR REMOVING
RETROPERITONEALTUMORS
WITH EXTENSIVE
CAVOATRIAL INVOLVEMENT
To the Editor:
The authors compare beating
heart cardiopulmonary bypass (CPB)
and hypothermic circulatory arrest
(HCA) for removing retroperitoneal
tumors with extensive cavoatrial in-
volvement.1 They included in their se-
ries retroperitoneal renal tumors with
level III-IV tumor thrombus
